@article{Lipworth_B-2021_58004,
title = {High-dose budesonide for early COVID-19},
author = {Lipworth, B. and Chan, R. and Misirovs, R.},
month = {dec},
year = {2021},
abstract = {We were encouraged by the results of the PRINCIPLE trial,which in vulnerable individuals showed inhaled budesonide to confer a non-significant –25% (95% CI –45 to 3) relative reduction in the composite coprimary endpoint of hospital admission or death, with the number needed to treat being 50.Notably, the study had 90% power to detect a 50% reduction in the composite endpoint. The investigators appear to have attributed any protective effects of budesonide to its local glucocorticoid activity in the lung.},
pages = {2147-2147},
volume = {398},
issue = {10317},
journal = {The Lancet},
publisher = {Elsevier},
url = {https://doi.org/10.1016/S0140-6736(21)02440-5},
}
